ClinConnect ClinConnect Logo
Search / Trial NCT06866002

Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France - 3-year Follow-up

Launched by INSTITUT PASTEUR DE LILLE · Mar 4, 2025

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Risk Factors Precarious Accelerated Aging (Pre) Diabetes

ClinConnect Summary

This clinical trial is looking at how different factors related to a person's social and economic situation can affect their risk of developing diabetes and signs of aging more quickly. Researchers in northern France are focusing on a large group of people, many of whom face economic challenges, to better understand why some populations are more at risk for these health issues. They previously studied over 2,200 volunteers who came in for health check-ups and are now planning to follow up with participants after three years to see how their health may have changed.

To be eligible for this follow-up study, participants must have taken part in the earlier PrévenDIAB study. It’s important to note that people who are currently involved in another clinical trial or who are unable to schedule their follow-up won't be able to participate. During the follow-up, participants will receive another health check-up and will be asked similar questions to those asked in the first study. This will help researchers gather more information on diabetes risk factors and understand how to address health inequalities in the community.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participant in the PrévenDIAB study
  • Exclusion Criteria:
  • Subject participating in another clinical study or in a period of exclusion from another study and incompatible with PrévenDIAB-2 follow-up
  • Refusal to participate in study
  • Scheduling impossible

About Institut Pasteur De Lille

Institut Pasteur de Lille is a prominent research institution in France dedicated to advancing medical science and public health through innovative research and clinical trials. Recognized for its expertise in infectious diseases, immunology, and vaccine development, the institute fosters collaboration among multidisciplinary teams to translate scientific discoveries into effective therapies and preventive measures. With a strong commitment to ethical standards and patient safety, Institut Pasteur de Lille plays a crucial role in addressing global health challenges and enhancing the quality of care through rigorous clinical research and development initiatives.

Locations

Hauts De France, , France

Patients applied

0 patients applied

Trial Officials

Philippe FROGUEL

Study Chair

PhD PRECIDIAB

Matthias VANDESQUILLE

Study Director

PhD PRECIDIAB

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported